key: cord-0731449-8kt460dc
authors: Bermingham, W.H.; Ardern‐Jones, M.R.; Huissoon, A.P.; Krishna, M.T.
title: Forewarned is Forearmed: chronic spontaneous urticaria as a potential risk to effective SARS‐COV‐2 vaccine uptake and global public health
date: 2021-05-20
journal: Br J Dermatol
DOI: 10.1111/bjd.20495
sha: 15471cc4fe51811672c02b59eb5f8241ab094b08
doc_id: 731449
cord_uid: 8kt460dc

Chronic spontaneous urticaria and angioedema (CSU/A) is a common condition with an estimated global point prevalence of 0.7% (95% C.I, 0.2‐1.4)(1), higher in non‐White populations. Symptoms present as an ‘allergy mimic’ but are underpinned by non‐specific, non‐IgE‐mediated mast cell histamine release. The combination of common population prevalence and likelihood of vaccines precipitating symptoms in those with CSU/A presents an immediate risk to the SARS‐COV‐2 global vaccine program.

This article is protected by copyright. All rights reserved necessitating 60-90% herd immunity to block viral transmission will require high vaccine uptake (2) .

Public fear/perception of adverse events (AEs) is a significant contributor to vaccine hesitancy (3) . For SARS-COV-2 vaccines, latest US CDC data showed that anaphylaxis occurred in 4.7 and 2.5 per million doses of Pfizer-BionTech (9,943,247 doses) and Moderna vaccines (7,581,429) respectively (4) . However, frequency of other AEs, including urticaria and angioedema, is not established. For other vaccines, rates of urticaria as high as 5-13% are quoted for toxoid vaccines (5) . A study of the 2009 monovalent H1N1 influenza vaccine reported hives/urticaria as the most common 'hypersensitivity reaction' within 48 hours of vaccination (6) . Such symptoms, post-vaccination, may occur through IgE-mediated or non-IgE-mediated pathways. The distinction is important as whilst IgEmediated reactions would be a contraindication for a second dose of the same vaccine, this is not the case for the non-IgE mediated responses due to CSU/A. Diagnosis can be challenging, compounded by a global unmet demand for allergy specialists, particularly in LICs and LMICs.

Clinical experience suggests that vaccines are recognised precipitants of symptoms in CSU/A, although data in this area are sparse. Magen et al recently reported a case series regarding development of CSU following recent receipt of a range of vaccines, (hepatitis B, human papilloma virus, influenza, yellow fever, and combination DTP vaccines) (7).

The AWARE study (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) highlighted that CSU/A is often under treated and associated with high healthcare use (8) . Importantly, the burden of CSU/A was significantly greater in Central/South American patients (compared to European), possibly due to weaker health service framework, lack of access to specialist care and treatments (particularly omalizumab). It is likely that there is a similar or a higher burden of uncontrolled disease in LICs/LMICs in Africa and Asia (3, 8) .

Hence, there is a clear need for a proactive approach for CSU/A during the SARS-COV-2 vaccination program. A proportion of CSU/A patients can be expected to experience worsened symptoms in association with recent SARS-COV-2 vaccination, which may be easily misinterpreted as 'vaccine allergy'. Given the relatively high prevalence of CSU/A, burden is likely to be significant. Table-1 Without intervention, the impact is likely to be multifactorial. Incorrect labelling as 'vaccine allergic' will have detrimental consequences on SARS-COV-2 immunity at patient and population levels. Vaccine safety surveillance data may exaggerate the perceived risk of IgE-mediated reactions. Furthermore, severe urticaria/angioedema flares may require short course corticosteroid treatment, which could interfere with vaccine related immune responses. Whilst data for CSU/A are unavailable, >10mg/day prednisolone (medium-long term treatment) for rheumatological conditions was found to have a measurable impact on humoral immune response to vaccines (9) . Antihistamines, however, are well established, safe and relatively inexpensive therapy used both as prophylaxis and for the management of acute flares in CSU/A patients. Some reports suggest a potential protective anti-COVID effect from antihistamines, but to date, there are no data to suggest antihistamines reduce immunogenicity of SARS-COV-2 vaccination.

This article is protected by copyright. All rights reserved There are currently no data regarding the risk of CSU/A exacerbation and SARS-COV-2 vaccination. However, in view of the importance of this issue, we propose the following pragmatic advice for CSU/A patients, which the authors have previously employed to abrogate symptom flares in settings such as intercurrent infection, surgical procedures and allergen-specific immunotherapy (desensitisation):

1. A diagnosis of CSU/A does not increase the risk of an IgE-mediated reaction to SARS-COV-2 vaccination. 2. Vaccination may cause a flare of CSU/A, which may be confused with 'vaccine allergy'. 3. Recommend regular antihistamines for 2 days prior and after receiving the vaccine in patients with CSU/A. Patients on long-term antihistamines may be advised to increase their usual dose for this period (under clinical supervision).

This should be combined with advice to clinicians managing patients in acute and emergency settings to avoid prescribing corticosteroids for acute urticaria and/or angioedema, unless there is clear objective evidence for anaphylaxis or for a severe flare not responding to high dose antihistamines. Finally, vaccine safety surveillance programs should specifically assess data relating to patients with a diagnosis of CSU/A to better inform future management of this common, yet poorly understood condition.

Prevalence of chronic urticaria in children and adults across the globe: Systematic review with metaanalysis

Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination

Evidence-Based Strategies for Clinical Organizations to Address COVID-19 Vaccine Hesitancy

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US

Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: Reports to VAERS

Chronic Spontaneous Urticaria Following Vaccination

Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study

COVID-19 vaccination and antirheumatic therapy

This article is protected by copyright. All rights reserved